戻る Agenda
Executive Forum (Invitation Only): Europe’s Readiness to Face the Requirements of Future Therapies
Session Chair(s)
Duane Schulthess, MBA
Chief Executive Officer
Vital Transformation LLC, United States
Effective therapies are coming fast and furious, often with higher and higher pricing. While effective treatments increase efficiency and reduce treatment costs, there are no processes nor mechanisms that exist in Europe to claw back funding from regional budgets that create savings locally. What needs to change, if anything? What evidence and systems need to be developed to fix this problem, or is it not a problem at all? This session will discuss: • The market for Orphan indications is growing 11% per year, and will be 25% of drug spending by the year 2025. Is this a good or a bad thing? • Playing Hot Potato with Pricing - How do we build a reimbursement system fit for purpose?
Speaker(s)
Panelist
Alexander Natz, JD
European Confederation of Pharmaceutical Entrepreneurs, Belgium
Secretary General
Panelist
Bettina Ryll
MPNE, Vision Zero Cancer, Sweden
Member of the First EU Cancer Mission Board
Panel Discussion
Tomas Salmonson, DrMed, PHD
Critical Path Institute, Netherlands
Panelist
Anja Schiel, PHD
Norwegian Medical Products Agency (NOMA), Norway
Special Advisor, Lead Methodologist/Statistician; NOMA